{
    "id": "5e7744c3835f4e4777000005",
    "question": "Can leuprorelin acetate be used as androgen deprivation therapy?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to consider the properties and uses of leuprolide acetate as described in the provided documents. Leuprolide acetate is a gonadotropin-releasing hormone (GnRH) agonist, which is used to treat various conditions, including prostate cancer. According to Document [0], leuprolide acetate is approved for the treatment of prostate cancer, along with other GnRH agonists like goserelin, histrelin, buserelin, and triptorelin. It is used to reduce serum testosterone concentrations and effects in prostate cancer patients. In Document [2], it is mentioned that GnRH analogs, including leuprolide acetate, produce effective gonadal suppression when blood levels are continuous rather than pulsatile. This suggests that leuprolide acetate can be used as androgen deprivation therapy for prostate cancer. Furthermore, in Document [26], it is stated that most patients who are treated with a GnRH agonist receive an antiandrogen for the first 2\u20134 weeks of treatment to protect against the flare, which implies that leuprolide acetate can be used as part of a combined therapy regimen for androgen deprivation. Therefore, based on the information provided, leuprolide acetate can be used as androgen deprivation therapy for prostate cancer.\", \"answer_choice\": \"A\"}",
    "snippets": [
        {
            "id": "Pharmacology_Katzung_4182",
            "title": "Pharmacology_Katzung",
            "content": "Prostate cancer\u2014Androgen deprivation therapy is the primary medical therapy for prostate cancer. Combined antiandrogen therapy with continuous GnRH agonist and an androgen receptor antagonist is as effective as surgical castration in reducing serum testosterone concentrations and effects. Leuprolide, goserelin, histrelin, buserelin, and triptorelin are approved for this indication. The preferred formulation is one of the long-acting depot forms that provide 1, 3, 4, 6, or 12 months of active drug therapy. During the first 7\u201310 days of GnRH analog therapy, serum testosterone levels increase because of the agonist action of the drug; this can precipitate pain in patients with bone metastases, and tumor growth and neurologic symptoms in patients with vertebral metastases. It can also temporarily worsen symptoms of urinary obstruction. Such tumor flares can usually be avoided with the concomitant administration of an androgen receptor antagonist (flutamide, bicalutamide, or nilutamide)"
        },
        {
            "id": "Pharmacology_Katzung_4604",
            "title": "Pharmacology_Katzung",
            "content": "CHAPTER 40 The Gonadal Hormones & Inhibitors 743 several well-documented applications. The treatment of advanced prostatic carcinoma often requires orchiectomy or large doses of estrogens to reduce available endogenous androgen. The psychological effects of the former and gynecomastia produced by the latter make these approaches undesirable. As noted in Chapter 37, the GnRH analogs, such as goserelin, nafarelin, buserelin, and leuprolide acetate, produce effective gonadal suppression when blood levels are continuous rather than pulsatile (see Chapter 37 and Figure 40\u20136). The potential usefulness of antiandrogens in the treatment of patients producing excessive amounts of testosterone has led to the search for effective drugs that can be used for this purpose. Several approaches to the problem, especially inhibition of synthesis and receptor antagonism, have met with some success."
        },
        {
            "id": "InternalMed_Harrison_6361",
            "title": "InternalMed_Harrison",
            "content": "Prostate cancer is classically treated by androgen deprivation. Diethylstilbestrol (DES) acting as an estrogen at the level of the hypothalamus to downregulate hypothalamic luteinizing hormone (LH) production results in decreased elaboration of testosterone by the testicle. For this reason, orchiectomy is equally as effective as moderate-dose DES, inducing responses in 80% of previously untreated patients with prostate cancer but without the prominent cardiovascular side effects of DES, including thrombosis and exacerbation of coronary artery disease. In the event that orchiectomy is not accepted by the patient, testicular androgen suppression can also be effected by luteinizing hormone\u2013releasing hormone (LHRH) agonists such as leuprolide and goserelin. These agents cause tonic stimulation of the LHRH receptor, with the loss of its normal pulsatile activation resulting in decreased output of LH by the anterior pituitary. Therefore, as primary hormonal manipulation in prostate cancer,"
        },
        {
            "id": "Pathology_Robbins_4183",
            "title": "Pathology_Robbins",
            "content": "hormone (LHRH). In addition, there are many new therapies that reduce androgen synthesis or signaling in metastatic prostate cancer. Although anti-androgen therapy induces remissions, androgen-independent clones almost invariably emerge, leading to rapid disease progression and death. As discussed earlier, these mutant clones commonly continue to express many genes that in normal prostate are androgen-dependent, suggesting that mechanisms arise to reactivate androgen signaling, even in the context of androgen deprivation therapy."
        },
        {
            "id": "InternalMed_Harrison_540",
            "title": "InternalMed_Harrison",
            "content": "In patients with prostate cancer and distant metastases, androgen deprivation therapy (ADT) improves survival. In patients with locally advanced disease, ADT in combination with external-beam radiation or as an adjuvant therapy (after prostatectomy and pelvic lymphadenectomy) also has been shown to improve survival. However, ADT is being increasingly used as primary therapy in men with localized disease and in men encountering biochemical recurrence without clear evidence of survival advantage. Because most men with prostate cancer die of conditions other than their primary malignancy, recognition and management of these adverse effects is paramount."
        },
        {
            "id": "Pharmacology_Katzung_6022",
            "title": "Pharmacology_Katzung",
            "content": "Prostate cancer was the second cancer shown to be responsive to hormonal manipulation. The treatment of choice for patients with metastatic prostate cancer is elimination of testosterone production by the testes through either surgical or chemical castration. Bilateral orchiectomy or estrogen therapy in the form of diethylstilbestrol was previously used as first-line therapy. Presently, the use of luteinizing hormone-releasing hormone (LHRH) agonists\u2014including leuprolide and goserelin agonists, alone or in combination with an antiandrogen (eg, flutamide, bicalutamide, or nilutamide)\u2014 is the preferred approach (see Chapter 40). There appears to be no survival advantage of total androgen blockade using a combination of LHRH agonist and antiandrogen agent compared with single-agent therapy. Abiraterone, an inhibitor of steroid synthesis (see Chapter 39), has recently been approved. Hormonal treatment reduces symptoms\u2014especially bone pain\u2014in 70\u201380% of patients and may cause a significant"
        },
        {
            "id": "InternalMed_Harrison_6362",
            "title": "InternalMed_Harrison",
            "content": "of the LHRH receptor, with the loss of its normal pulsatile activation resulting in decreased output of LH by the anterior pituitary. Therefore, as primary hormonal manipulation in prostate cancer, one can choose orchiectomy or leuprolide, but not both. The addition of androgen receptor blockers, including flutamide or bicalutamide, is of uncertain additional benefit in extending overall response duration; the combined use of orchiectomy or leuprolide plus flutamide is referred to as total androgen blockade. Enzalutamide also binds to the androgen receptor and antagonizes androgen action in a mechanistically distinct way. Somewhat analogous to inhibitors of aromatase, agents have been derived that inhibit testosterone and other androgen synthesis in the testis, adrenal gland, and prostate tissue. Abiraterone inhibits 17 \u03b1-hydroxylase/C17,20 lyase (CYP 17A1) and has been shown to be active in prostate cancer patients experiencing progression despite androgen blockade."
        },
        {
            "id": "InternalMed_Harrison_7459",
            "title": "InternalMed_Harrison",
            "content": "Intermittent Androgen Deprivation Therapy (IADT) The use of hormones in an \u201con-and-off\u201d approach was initially proposed as a way to prevent the selection of cells that are resistant to androgen depletion and to reduce side effects. The hypothesis is that by allowing endogenous testosterone levels to rise, the cells that survive androgen depletion will induce a normal differentiation pathway. It is postulated that by allowing the surviving cells to proliferate in the presence of androgen, sensitivity to subsequent androgen depletion will be retained and the chance of developing a castration-resistant state will be reduced. Applied in the clinic, androgen depletion is continued for 2\u20136 months beyond the point of maximal response. Once treatment is stopped, endogenous testosterone levels increase, and the symptoms associated with hormone treatment abate. PSA levels also begin to rise, and at some level, treatment is restarted. With this approach, multiple cycles of regression and"
        },
        {
            "id": "InternalMed_Harrison_6138",
            "title": "InternalMed_Harrison",
            "content": "which block the conversion of androgens to estrogens in breast and subcutaneous fat tissues, have demonstrated improved clinical efficacy compared with tamoxifen and are often used as first-line therapy in patients with ER-positive disease. A number of approaches have been developed for blocking androgen stimulation of prostate cancer, including decreasing production (e.g., orchiectomy, luteinizing hormone\u2013releasing hormone agonists or antagonists, estrogens, ketoconazole, and inhibitors of enzymes such as CYP17 involved in androgen production) and AR blockers (Chap. 108)."
        },
        {
            "id": "InternalMed_Harrison_537",
            "title": "InternalMed_Harrison",
            "content": "Testosterone Therapy in Men with History of Prostate Cancer A history of prostate cancer has historically been considered a contraindication for testosterone therapy. This guidance is based on observations that testosterone promotes the growth of metastatic prostate cancer. Metastatic prostate cancer generally regresses after orchidectomy and androgen deprivation therapy. Androgen receptor signaling plays a central role in maintaining growth of normal prostate and prostate cancer. PSA levels are lower in hypogonadal men and increase after testosterone therapy. Prostate volume is lower in hypogonadal men and increases after testosterone therapy to levels seen in age-matched controls."
        },
        {
            "id": "Pharmacology_Katzung_4192",
            "title": "Pharmacology_Katzung",
            "content": "B. Advanced Prostate Cancer Degarelix and abarelix are approved for the treatment of symptomatic advanced prostate cancer. These GnRH antagonists reduce concentrations of gonadotropins and androgens more rapidly than GnRH agonists and avoid the testosterone surge seen with GnRH agonist therapy. When used for controlled ovarian stimulation, ganirelix and cetrorelix are well tolerated. The most common adverse effects are nausea and headache. During the treatment of men with prostate cancer, degarelix caused injection-site reactions and increases in liver enzymes. Like continuous treatment with a GnRH agonist, degarelix and abarelix lead to signs and symptoms of androgen deprivation, including hot flushes and weight gain."
        },
        {
            "id": "Surgery_Schwartz_11740",
            "title": "Surgery_Schwartz",
            "content": "years for metastasis to appear on imaging studies.138 Once prostate cancer metastasizes, it is no longer curable. Medications that lower serum testosterone or androgen receptor blockers are able to control the disease, often for years. In addition, chemotherapy, immunotherapy, and radioisotope therapy at different stages of the disease increase the life expectancy of the patients or improve the quality of life. The cancer inevitably becomes resis-tant to these treatments. Nevertheless, patients with incurable prostate cancer can live many years, and a large number die of causes other than prostate cancer.Over the past few years, we have witnessed major devel-opments in the management of metastatic castrate resistant prostate cancer (mCRPC). New agents that interrupt androgen synthesis (e.g., abiraterone acetate)139,140 and new modulators of androgen receptors (e.g., enzalutamide)141,142 have significantly improved the life expectancy of patients with both androgen sensitive and"
        },
        {
            "id": "InternalMed_Harrison_7470",
            "title": "InternalMed_Harrison",
            "content": "by the CYP17 inhibitor abiraterone acetate, which lowers androgen levels in the tumor, adrenal glands, and testis, and the next-generation antiandrogen enzalutamide, which not only has a higher binding affinity to the AR relative to first-generation compounds, but uniquely inhibits nuclear location and DNA binding of the receptor complex. Both abiraterone acetate and enzalutamide were first approved for postchemotherapy treated patients on the basis of placebo-controlled phase III trials\u2014a further indication that these tumors are not uniformly hormone-refractory. The indication for abiraterone acetate was later expanded to the prechemotherapy setting, based on a second trial using a co-primary endpoint of radiographic progression\u2013free survival and overall survival. Similar results were seen with enzalutamide, for which an expanded indication is also anticipated. Alpharadin (radium-223 chloride), an alpha-emitting bone-seeking radioisotope, has been shown to prolong life in patients"
        },
        {
            "id": "InternalMed_Harrison_6363",
            "title": "InternalMed_Harrison",
            "content": "Tumors that respond to a primary hormonal manipulation may frequently respond to second and third hormonal manipulations. Thus, breast tumors that had previously responded to tamoxifen have, on relapse, notable response rates to withdrawal of tamoxifen itself or to subsequent addition of an aromatase inhibitor or progestin. Likewise, initial treatment of prostate cancers with leuprolide plus flutamide may be followed after disease progression by response to withdrawal of flutamide. These responses may result from the removal Chapter 103e Principles of Cancer Treatment of antagonists from mutant steroid hormone receptors that have come to depend on the presence of the antagonist as a growth-promoting influence."
        },
        {
            "id": "Pharmacology_Katzung_4183",
            "title": "Pharmacology_Katzung",
            "content": "worsen symptoms of urinary obstruction. Such tumor flares can usually be avoided with the concomitant administration of an androgen receptor antagonist (flutamide, bicalutamide, or nilutamide) (see Chapter 40). Within about 2 weeks, serum testosterone levels fall to the hypogonadal range."
        },
        {
            "id": "InternalMed_Harrison_7452",
            "title": "InternalMed_Harrison",
            "content": "Testosterone-Lowering Agents Medical therapies that lower testosterone levels include the gonadotropin-releasing hormone (GnRH) agonists/antagonists, 17,20-lyase inhibitors, CYP17 inhibitors, estrogens, and progestational agents. Of these, GnRH analogues such as leuprolide acetate and goserelin acetate initially produce a rise in luteinizing hormone and follicle-stimulating hormone, followed by a downregulation of receptors in the pituitary gland, which effects a chemical castration. They were approved on the basis of randomized comparisons showing an improved safety profile (specifically, reduced cardiovascular toxicities) relative to diethylstilbestrol (DES), with equivalent potency. The initial rise in testosterone may result in a clinical flare of the disease. As such, these agents are relatively contraindicated in men with significant obstructive symptoms, cancer-related pain, or spinal cord compromise. GnRH antagonists such as degarelix achieve castrate levels of testosterone"
        },
        {
            "id": "Pathology_Robbins_4182",
            "title": "Pathology_Robbins",
            "content": "The most common treatments for clinically localized prostate cancer are radical prostatectomy and radiotherapy. The prognosis after radical prostatectomy is based on the pathologic stage, whether the margins of the resected specimens are free of tumor, and Gleason grade. The Gleason grade, clinical stage, and serum PSA values are important predictors of outcome after radiotherapy. Because many prostate cancers follow an indolent course, active surveillance (\u201cwatchful waiting\u201d) is an appropriate approach for older men, patients with significant comorbidity, or even some younger men with low serum PSA values and small, low-grade cancers. Advanced metastatic carcinoma is treated by androgen deprivation, either by orchiectomy or by administration of synthetic agonists of luteinizing hormone\u2013releasing hormone (LHRH). In addition, there are many new therapies that reduce androgen synthesis or signaling in metastatic prostate cancer. Although anti-androgen therapy induces remissions,"
        },
        {
            "id": "Gynecology_Novak_5525",
            "title": "Gynecology_Novak",
            "content": "Administration of GnRH agonists may allow the differentiation of androgen produced by adrenal sources from that of ovarian sources (47). It was shown to suppress ovarian steroids to castrate levels in patients with PCOS (104). Treatment with leuprolide acetate given intramuscularly every 28 days decreases hirsutism and hair diameter in both idiopathic hirsutism and hirsutism secondary to PCOS (105). Ovarian androgen levels are significantly and selectively suppressed. The addition of OC or estrogen replacement therapy to GnRH agonist treatment (addback therapy) prevents bone loss and other side effects of menopause, such as hot \ufb02ushes and genital atrophy. The hirsutism-reducing effect is retained (102,106). Suppression of hirsutism is not potentiated by the addition of estrogen replacement therapy to GnRH agonist treatment (107)."
        },
        {
            "id": "Pediatrics_Nelson_3660",
            "title": "Pediatrics_Nelson",
            "content": "Long-acting, superactive analogs of GnRH (leuprolide depot, histrelin depot) are the treatment of choice for central precocious puberty. They suppress gonadotropin secretion by downregulating GnRH receptors in the pituitary gonadotropes (Table 174-5), causing gonadal secretion to revert to the prepubertal state. Boys with GnRH-independent premature Leydig cell and germ cell maturation do not respond to GnRH analogs but require treatment with an inhibitor of testosterone synthesis (e.g., ketoconazole), an antiandrogen (e.g., spironolactone), or an aromatase inhibitor (e.g., testolactone or letrozole). Patients with precocious puberty from a hormone-secreting tumor require surgical removal, if possible. The precocious puberty of the McCune-Albright syndrome is GnRH independent and unresponsive to therapy with GnRH Autonomous ovarian cysts Medroxyprogesterone acetate Inhibition of ovarian steroidogenesis; regression of cyst (inhibition of FSH release)"
        },
        {
            "id": "Gynecology_Novak_5533",
            "title": "Gynecology_Novak",
            "content": "Flutamide Flutamide, a pure nonsteroidal antiandrogen, is approved for treatment of advanced prostate cancer. Its mechanism of action is inhibition of nuclear binding of androgens in target tissues. Although it has a weaker affinity to the androgen receptor than spironolactone or cyproterone acetate, larger doses (250 mg given two or three times daily) may compensate for the reduced potency. Flutamide is a weak inhibitor of testosterone biosynthesis."
        },
        {
            "id": "Pharmacology_Katzung_4598",
            "title": "Pharmacology_Katzung",
            "content": "H. Aging Androgen production falls with age in men and may contribute to the decline in muscle mass, strength, and libido. Preliminary studies of androgen replacement in aging males with low androgen levels show an increase in lean body mass and hematocrit and a decrease in bone turnover. However, many factors other than deficient androgen production contribute to these effects of aging. Longer studies will be required to assess the usefulness of this therapy."
        },
        {
            "id": "InternalMed_Harrison_7466",
            "title": "InternalMed_Harrison",
            "content": "Castration-resistant prostate cancer (CRPC) is defined as disease that progresses despite androgen suppression by medical or surgical therapies where the measured levels of testosterone are 50 ng/ mL or lower. The rise in PSA indicates continued signaling through the AR signaling axis, the result of a series of oncogenic changes that include overexpression of androgen biosynthetic enzymes that can lead to increased intratumoral androgens, and overexpression of the receptor itself that enables signaling to occur even in the setting of low levels of androgen. The majority of CRPC cases are not \u201chormone-refractory,\u201d and considering them as such can deny patients safe and effective treatment. CRPC can manifest in many ways. For some, it is a rise in PSA with no change in radiographs and no new symptoms. In others, it is a rising PSA and progression in bone with or without symptoms of disease. Still others will show soft tissue disease with or without osseous metastases, and others have"
        },
        {
            "id": "InternalMed_Harrison_7458",
            "title": "InternalMed_Harrison",
            "content": "586 been shown to be superior to androgen depletion monotherapies and are no longer recommended. In practice, most patients who are treated with a GnRH agonist receive an antiandrogen for the first 2\u20134 weeks of treatment to protect against the flare."
        },
        {
            "id": "InternalMed_Harrison_3819",
            "title": "InternalMed_Harrison",
            "content": "ENdOCRINOLOgIC Androgens increase libido, but their exact role in erectile function is unclear. Individuals with castrate levels of testosterone can achieve erections from visual or sexual stimuli. Nonetheless, normal levels of testosterone appear to be important for erectile function, particularly in older males. Androgen replacement therapy can improve depressed erectile function when it is secondary to hypogonadism; however, it is not useful for ED when endogenous testosterone levels are normal. Increased prolactin may decrease libido by suppressing gonadotropin-releasing hormone (GnRH), and it also leads to decreased testosterone levels. Treatment of hyperprolactinemia with dopamine agonists can restore libido and testosterone."
        },
        {
            "id": "InternalMed_Harrison_7456",
            "title": "InternalMed_Harrison",
            "content": "Most reported randomized trials suggest that the cancer-specific outcomes are inferior when antiandrogens are used alone. Bicalutamide, even at 150 mg (three times the recommended dose), was associated with a shorter time to progression and inferior survival compared to surgical castration for patients with established metastatic disease. Nevertheless, some men may accept the trade-off of a potentially inferior cancer outcome for an improved quality of life. Combined androgen blockade, the administration of an antiandrogen plus a GnRH analogue or surgical orchiectomy, and triple androgen blockade, which includes the addition of a 5ARI, have not"
        },
        {
            "id": "InternalMed_Harrison_7451",
            "title": "InternalMed_Harrison",
            "content": "Standard treatment is to deplete/lower androgens by medical or surgical means and/or to block androgen binding to the AR with antiandrogens. More than 90% of male hormones originate in the testes; <10% are synthesized in the adrenal gland. Surgical orchiectomy is the \u201cgold standard\u201d but is rarely used due to the availability of effective medical therapies and the more widespread use of hormones on an intermittent basis by which patients are treated for defined periods of time, following which the treatments are intentionally discontinued (discussed further below) (Fig. 115-3)."
        },
        {
            "id": "InternalMed_Harrison_7461",
            "title": "InternalMed_Harrison",
            "content": "Outcomes of Androgen Depletion The anti\u2013prostate cancer effects of the various androgen depletion/blockade strategies are similar, and the outcomes predictable: an initial response, then a period of stability in which tumor cells are dormant and nonproliferative, followed after a variable period of time by a rise in PSA and tumor regrowth as a castration-resistant lesion that for most men is invariably lethal. Androgen depletion is not curative because cells that survive castration are present when the disease is first diagnosed. Considered by disease manifestation, PSA levels return to normal in 60\u201370% of cases, and measurable lesions regress in about 50%; improvements in bone scan occur in 25% of cases, but the majority of cases remain stable. The duration of response and survival is inversely proportional to disease extent at the time androgen depletion is first started, whereas the degree of PSA decline at 6 months has been shown to be prognostic. In a large-scale trial, PSA nadir"
        },
        {
            "id": "Gynecology_Novak_5380",
            "title": "Gynecology_Novak",
            "content": "Antiandrogens Spironolactone decreases androgen production and competes with androgens at the androgen receptor. Side effects include diuresis and dysfunctional uterine bleeding. The use of spironolactone is typically combined with oral contraceptives to avoid irregular bleeding and to prevent pregnancy from occurring while on spironolactone. Flutamide is approved by the U.S. Food and Drug Administration (FDA) for adjuvant therapy in prostatic cancer and for treatment of hirsutism. Its effects are similar to those of spironolactone (132). Liver function should be monitored because of the rare complication of hepatotoxicity. Cyproterone acetate, a strong progestin and antiandrogen, is used abroad but is not available in the United States. It is usually administered in combination with ethinyl estradiol in an oral contraceptive. By decreasing circulating androgen and LH levels, and by inducing antagonism of androgen effects at the peripheral level, cyproterone acetate is effective in"
        },
        {
            "id": "Surgery_Schwartz_4058",
            "title": "Surgery_Schwartz",
            "content": "the ligand binding domains, lead to ligand-independent activation of the receptor, mediate resistance to aromatase inhibitors, and are associated with shorter survival.349 Reported incidence of these mutations are variable (20%\u201330%) based on prior exposure to aroma-tase inhibitors and are uncommon in primary breast cancers. Clinical trials evaluating novel selective estrogen receptor degraders with potential activity against these mutations are in progress.Ablative Endocrine TherapyIn the past, adrenalectomy and/or hypophysectomy were the pri-mary endocrine modalities used to treat metastatic breast cancer, but today these approaches are seldom used. In women who are premenopausal at diagnosis, ovarian ablation can be accomplished by oophorectomy or ovarian radiation. Ovarian suppression can be accomplished by the use of gonadotrophin-hormone releasing hormone agonists, such as goserelin or leuprolide. Evaluation of the combination of goserelin with tamoxifen vs."
        },
        {
            "id": "InternalMed_Harrison_7463",
            "title": "InternalMed_Harrison",
            "content": "An active question is whether hormones should be given in the adjuvant setting after surgery or radiation treatment of the primary tumor or whether to wait until PSA recurrence, metastatic disease, or symptoms are documented. Trials in support of early therapy have often been underpowered relative to the reported benefit or have been criticized on methodologic grounds. One trial showing a survival benefit for patients treated with radiation therapy and 3 years of androgen depletion, relative to radiation alone, was criticized for the poor outcomes of the control group. Another showing a survival benefit for patients with positive lymph nodes who were randomized to immediate medical or surgical castration compared to observation (p = .02) was criticized because the confidence intervals around the 5and 8-year survival distributions for the two groups overlapped. A large randomized study comparing early to late hormone treatment (orchiectomy or GnRH analogue) in patients with locally"
        },
        {
            "id": "InternalMed_Harrison_7455",
            "title": "InternalMed_Harrison",
            "content": "Antiandrogens First-generation nonsteroidal antiandrogens such as flutamide, bicalutamide, and nilutamide block ligand binding to the AR and were initially approved to block the disease flare that may occur with the rise in serum testosterone associated with GnRH agonist therapy. When antiandrogens are given alone, testosterone levels typically increase above baseline, but relative to testosterone-lowering therapies, they cause fewer hot flushes, less of an effect on libido, less muscle wasting, fewer personality changes, and less bone loss. Gynecomastia remains a significant problem but can be alleviated in part by tamoxifen."
        },
        {
            "id": "InternalMed_Harrison_6895",
            "title": "InternalMed_Harrison",
            "content": "to endocrine therapy, an endocrine treatment should be attempted in virtually every patient with metastatic breast cancer. Potential endocrine therapies are summarized in Table 108-4. The choice of endocrine therapy is usually determined by toxicity profile and availability. In most postmenopausal patients, the initial endocrine therapy should be an aromatase inhibitor rather than tamoxifen. For the subset of postmenopausal women who are estrogen receptor\u2013positive but also HER2/neu-positive, response rates to aromatase inhibitors are substantially higher than to tamoxifen. Aromatase inhibitors are not used in premenopausal women because their hypothalamus can respond to estrogen deprivation by producing gonadotropins that promote estrogen synthesis. Newer \u201cpure\u201d antiestrogens that are free of agonistic effects are also effective. Cases in which tumors shrink in response to tamoxifen withdrawal (as well as withdrawal of pharmacologic doses of estrogens) have been reported. A series of"
        }
    ],
    "scores": [
        0.03794936291613757,
        0.03494573586164833,
        0.03389812499414192,
        0.033497598013853574,
        0.03134364623633107,
        0.0297029702970297,
        0.028321678321678322,
        0.028004477212448597,
        0.027756751355366677,
        0.026532975782601803,
        0.025947289899143383,
        0.02451694461188132,
        0.024140526256197285,
        0.02410788070017279,
        0.023642755094367997,
        0.023553394243049416,
        0.022595877473926253,
        0.021944039855310175,
        0.021517114699282854,
        0.02136609178313014,
        0.02114356232003291,
        0.019284243873802995,
        0.018957771787960466,
        0.018820591907174854,
        0.018812930577636458,
        0.01869643001954544,
        0.018219461697722567,
        0.01783749803551784,
        0.017470247177296307,
        0.01743877473652286,
        0.01743396226415094,
        0.01722349393775928
    ]
}